US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

89.33

-1.0300-1.14%

Post-market: 88.86-0.4660-0.52%16:07 EDT

Volume:1.79M

Turnover:158.55M

Market Cap:7.88B

PE:-44.44

High:90.97

Open:89.15

Low:86.40

Close:90.36

52wk High:110.18

52wk Low:14.51

Shares:88.17M

Float Shares:80.98M

Volume Ratio:1.26

T/O Rate:2.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0100

EPS(LYR):-1.9755

ROE:-22.98%

ROA:-19.81%

PB:8.25

PE(LYR):-45.22

Loading ...

Overview Company News Filings

Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints

THOMSON REUTERS

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Simply Wall St.

LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

MT Newswires Live

Spyre Therapeutics Announces Launch of Spy772 Program and Initiation of Phase 2 Skylight Trial in Hidradenitis Suppurativa

THOMSON REUTERS

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million

Spyre Therapeutics Inc : Jefferies Raises Target Price to $122 from $98

THOMSON REUTERS

Spyre Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim

Movement Alert｜Spyre Therapeutics Rises 11.41% in Regular Trading, Trading at $104.42

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":89.33,"timestamp":1788206400000,"preClose":90.36,"halted":0,"volume":1789404,"hourTrading":{"tag":"盘后","latestPrice":88.864,"preClose":89.33,"latestTime":"16:07 EDT","volume":131022,"amount":11704167.745380001,"timestamp":1788206873939,"change":-0.466,"changeRate":-0.005217,"amplitude":0.005217},"delay":0,"changeRate":-0.01139884904825145,"floatShares":80977000,"shares":88173800,"eps":-2.009956,"marketStatus":"Post-Mkt","change":-1.03,"latestTime":"08-31 16:09:53 EDT","open":89.15,"high":90.965,"low":86.4,"amount":158553630.75779998,"amplitude":0.05052,"askPrice":89.32,"askSize":3,"bidPrice":88.84,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.009956,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":90.36,"preHourTrading":{"tag":"盘前","latestPrice":88.13,"preClose":90.36,"latestTime":"09:29 EDT","volume":763,"amount":68221.45519000001,"timestamp":1788182999999,"change":-2.23,"changeRate":-0.024679,"amplitude":0.02479},"postHourTrading":{"tag":"盘后","latestPrice":88.864,"preClose":89.33,"latestTime":"16:07 EDT","volume":131022,"amount":11704167.745380001,"timestamp":1788206873939,"change":-0.466,"changeRate":-0.005217,"amplitude":0.005217},"volumeRatio":1.25811,"impliedVol":0.7207,"impliedVolPercentile":0.3904},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":80977000,"roa":"-19.81%","roe":"-22.98%","lyrEps":-1.975476,"volumeRatio":1.25811,"shares":88173800,"dividePrice":0,"high":90.965,"amplitude":0.05052,"preClose":90.36,"low":86.4,"week52Low":14.505,"pbRate":"8.25","week52High":110.175,"institutionHeld":0,"latestPrice":89.33,"committee":0.988072,"eps":-2.009956,"divideRate":0,"volume":1789404,"delay":0,"ttmEps":-2.009956,"open":89.15,"prevYearClose":32.76,"prevWeekClose":90.36,"prevMonthClose":98.33,"prevQuarterClose":88.78,"fiveDayClose":106.65,"twentyDayClose":94.93,"sixtyDayClose":78.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"SYRE","fiscalQuarterEnding":"2026/06","expectedEps":-0.71,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2026-05-05","symbol":"SYRE","fiscalQuarterEnding":"2026/03","expectedEps":-0.66,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2026-02-19","symbol":"SYRE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-04","symbol":"SYRE","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-08-05","symbol":"SYRE","fiscalQuarterEnding":"2025/06","expectedEps":-0.73,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.49}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5294,"buy":0.4118,"hold":0.0588,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4118,"analysts":17,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2026-08-28","current":-44.443759,"percent":0.049635,"low":-53.677585,"twenty":-18.037414,"median":-6.00579,"eighty":-4.082736,"high":-0.199399,"avg":-12.382014,"sd":13.405227,"marketCap":8254386729},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673},{"date":"2025-08-01","current":-4.902026,"twenty":-6.889009,"median":-4.488402,"eighty":-3.59611,"marketCap":1024199930},{"date":"2025-08-08","current":-4.450911,"twenty":-6.843738,"median":-4.500505,"eighty":-3.597671,"marketCap":920510630},{"date":"2025-08-15","current":-4.924039,"twenty":-6.770823,"median":-4.509171,"eighty":-3.60188,"marketCap":1018360185},{"date":"2025-08-22","current":-4.900675,"twenty":-6.760445,"median":-4.52404,"eighty":-3.616232,"marketCap":1013528108},{"date":"2025-08-29","current":-4.883151,"twenty":-6.744059,"median":-4.5525,"eighty":-3.624946,"marketCap":1009904051},{"date":"2025-09-05","current":-4.962006,"twenty":-6.704732,"median":-4.610273,"eighty":-3.625072,"marketCap":1026212310},{"date":"2025-09-12","current":-4.731283,"twenty":-6.670975,"median":-4.650968,"eighty":-3.630649,"marketCap":978495552},{"date":"2025-09-19","current":-4.474275,"twenty":-6.670975,"median":-4.610273,"eighty":-3.651563,"marketCap":925342707},{"date":"2025-09-26","current":-4.558971,"twenty":-6.651853,"median":-4.590463,"eighty":-3.659766,"marketCap":942858985},{"date":"2025-10-03","current":-4.667031,"twenty":-6.651853,"median":-4.640746,"eighty":-3.671275,"marketCap":965207340},{"date":"2025-10-10","current":-6.182794,"twenty":-6.639187,"median":-4.66411,"eighty":-3.682866,"marketCap":1278688323},{"date":"2025-10-17","current":-6.495292,"twenty":-6.589022,"median":-4.675298,"eighty":-3.682866,"marketCap":1343317350},{"date":"2025-10-24","current":-8.382293,"twenty":-6.651853,"median":-4.679157,"eighty":-3.689208,"marketCap":1733575542},{"date":"2025-10-31","current":-9.090497,"twenty":-6.704732,"median":-4.696933,"eighty":-3.700564,"marketCap":1880042140},{"date":"2025-11-07","current":-11.662076,"twenty":-6.790267,"median":-4.714264,"eighty":-3.706047,"marketCap":1737287790},{"date":"2025-11-14","current":-11.787083,"twenty":-6.900444,"median":-4.731283,"eighty":-3.707046,"marketCap":1755909901},{"date":"2025-11-21","current":-12.224606,"twenty":-6.988263,"median":-4.745208,"eighty":-3.707046,"marketCap":1821087291},{"date":"2025-11-28","current":-15.625828,"twenty":-7.239349,"median":-4.751954,"eighty":-3.713244,"marketCap":2327763900},{"date":"2025-12-05","current":-17.454049,"twenty":-7.296115,"median":-4.772037,"eighty":-3.728167,"marketCap":2600112276},{"date":"2025-12-12","current":-17.896781,"twenty":-7.380142,"median":-4.779357,"eighty":-3.742192,"marketCap":2666065586},{"date":"2025-12-19","current":-17.433215,"twenty":-7.489402,"median":-4.800924,"eighty":-3.751648,"marketCap":2597008591},{"date":"2025-12-26","current":-17.214453,"twenty":-7.525937,"median":-4.815979,"eighty":-3.763383,"marketCap":2564419896},{"date":"2026-01-02","current":-17.063404,"twenty":-7.573901,"median":-4.841253,"eighty":-3.771122,"marketCap":2541918178},{"date":"2026-01-09","current":-15.698748,"twenty":-7.596248,"median":-4.85056,"eighty":-3.792677,"marketCap":2338626798},{"date":"2026-01-16","current":-17.235288,"twenty":-7.641035,"median":-4.868549,"eighty":-3.827277,"marketCap":2567523581},{"date":"2026-01-23","current":-17.756149,"twenty":-7.65516,"median":-4.878917,"eighty":-3.836222,"marketCap":2645115711},{"date":"2026-01-30","current":-17.49051,"twenty":-7.716495,"median":-4.891913,"eighty":-3.850233,"marketCap":2605543725},{"date":"2026-02-06","current":-17.157159,"twenty":-7.797537,"median":-4.900675,"eighty":-3.876725,"marketCap":2555884762},{"date":"2026-02-13","current":-18.146794,"twenty":-7.885881,"median":-4.903471,"eighty":-3.891573,"marketCap":2703309809},{"date":"2026-02-20","current":-23.527864,"twenty":-7.934432,"median":-4.916265,"eighty":-3.909092,"marketCap":3504922382},{"date":"2026-02-27","current":-21.83597,"twenty":-8.038472,"median":-4.931737,"eighty":-3.918816,"marketCap":3389008076},{"date":"2026-03-06","current":-20.540487,"twenty":-8.323214,"median":-4.953617,"eighty":-3.922049,"marketCap":3187945256},{"date":"2026-03-13","current":-20.449399,"twenty":-8.618907,"median":-4.962688,"eighty":-3.925813,"marketCap":3173808027},{"date":"2026-03-20","current":-21.41089,"twenty":-8.906386,"median":-4.973688,"eighty":-3.927002,"marketCap":3323034338},{"date":"2026-03-27","current":-24.0474,"twenty":-8.969358,"median":-4.994463,"eighty":-3.931452,"marketCap":3732228593},{"date":"2026-04-02","current":-24.745746,"twenty":-9.172768,"median":-5.075907,"eighty":-3.931939,"marketCap":3840614019},{"date":"2026-04-10","current":-26.198104,"twenty":-9.23713,"median":-5.085831,"eighty":-3.944911,"marketCap":4066024290},{"date":"2026-04-17","current":-38.738151,"twenty":-9.365612,"median":-5.125877,"eighty":-3.981637,"marketCap":6012277252},{"date":"2026-04-24","current":-38.48249,"twenty":-9.54815,"median":-5.141783,"eighty":-3.990939,"marketCap":5972597947},{"date":"2026-05-01","current":-41.378125,"twenty":-11.574571,"median":-5.163524,"eighty":-3.996385,"marketCap":6422009203},{"date":"2026-05-08","current":-35.378246,"twenty":-11.912235,"median":-5.194337,"eighty":-4.002987,"marketCap":6348095594},{"date":"2026-05-15","current":-36.612371,"twenty":-12.227731,"median":-5.199556,"eighty":-4.01025,"marketCap":6569540789},{"date":"2026-05-22","current":-35.96869,"twenty":-12.66317,"median":-5.24323,"eighty":-4.012918,"marketCap":6454041922},{"date":"2026-05-29","current":-34.899115,"twenty":-14.84662,"median":-5.263514,"eighty":-4.014565,"marketCap":6262122753},{"date":"2026-06-05","current":-37.982008,"twenty":-15.625828,"median":-5.295394,"eighty":-4.016676,"marketCap":6815301535},{"date":"2026-06-12","current":-39.0903,"twenty":-15.934177,"median":-5.346464,"eighty":-4.018572,"marketCap":7014168004},{"date":"2026-06-18","current":-42.342582,"twenty":-16.532126,"median":-5.375072,"eighty":-4.022327,"marketCap":7597741224},{"date":"2026-06-26","current":-42.913667,"twenty":-16.744637,"median":-5.470693,"eighty":-4.034149,"marketCap":7700213903},{"date":"2026-07-02","current":-43.020141,"twenty":-17.038402,"median":-5.524211,"eighty":-4.045526,"marketCap":7719318979},{"date":"2026-07-10","current":-47.79209,"twenty":-17.157159,"median":-5.623342,"eighty":-4.04736,"marketCap":8575573733},{"date":"2026-07-17","current":-46.12579,"twenty":-17.21862,"median":-5.641652,"eighty":-4.048014,"marketCap":8276581215},{"date":"2026-07-24","current":-49.002526,"twenty":-17.305083,"median":-5.684807,"eighty":-4.051257,"marketCap":8792768335},{"date":"2026-07-31","current":-49.742539,"twenty":-17.37592,"median":-5.758017,"eighty":-4.05376,"marketCap":8925552415},{"date":"2026-08-07","current":-50.967094,"twenty":-17.454049,"median":-5.886958,"eighty":-4.070861,"marketCap":9118930466},{"date":"2026-08-14","current":-50.193372,"twenty":-17.542596,"median":-5.928557,"eighty":-4.072986,"marketCap":8980497659},{"date":"2026-08-21","current":-53.120702,"twenty":-17.704063,"median":-5.957984,"eighty":-4.07743,"marketCap":9504249805},{"date":"2026-08-28","current":-46.135027,"twenty":-18.037414,"median":-6.00579,"eighty":-4.082736,"marketCap":8254386729}],"updateTime":1788206994015},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662475498","title":"Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662475498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662475498?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175441","title":"Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175441?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":"Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350866/0/en/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-the-skyway-phase-2-trial-of-spy072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4007","RA","LFSC","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660406265","title":"Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660406265","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660406265?lang=en_us&edition=fundamental","pubTime":"2026-08-20 13:34","pubTimestamp":1787204046,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics stock reacts to new SPY772 program and SKYLIGHT trial launch\nSpyre Therapeutics (SYRE) is in focus after the company launched its SPY772 combination program and began SKYLIGHT, a Phase 2 proof of concept trial in Hidradenitis Suppurativa.\nBoth efforts target dual inhibition of TL1A and IL-17A/F in moderate to severe HS. The approach uses SPY072 alongside background bimekizumab therapy for around 150 adult participants.\nSee our latest analysis for Spyre Therapeutics.\nSpyre...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-after-its-spy772-pro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-after-its-spy772-pro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659173434","title":"LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659173434","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659173434?lang=en_us&edition=fundamental","pubTime":"2026-08-15 22:35","pubTimestamp":1786804513,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Spyre Therapeutics, with a price target of $129.00. Slutsky...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165757","title":"Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165757?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:40","pubTimestamp":1786635611,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS P...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","HCSG","BK4585","XLV","SYRE","LU0029874061.USD","BK4588","LABU","LU2065731478.USD","BK4581","PSIL","XBI","LFSC","BK4139","BK4137","LU2324357040.USD","BK4082","CMPS","TMDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916668","title":"Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916668","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658916668?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:55","pubTimestamp":1786456528,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Spyre Therapeutics today and set a price target of $130.00. Nierengarten covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658372967","title":"Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658372967","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658372967?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:30","pubTimestamp":1786429817,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-stereotaxis-stxs-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-stereotaxis-stxs-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","STXS","LABU","SYRE","XBI","LFSC","BK4137","HCSG","BK4581","LU0128526141.USD","TVRD","XLV","LU0029874061.USD","BK4007","BK4082","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658696533","title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658696533","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658696533?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:32","pubTimestamp":1786411952,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common sharesSpyre Therapeutics director Jeffrey W. Albers exercised stock options to buy 5,000 common shares at USD 10.39","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7DPBBq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893427","title":"Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893427","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893427?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:58","pubTimestamp":1786370315,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said Monday that it has launched SPY772, a program that combines SPY072, a long-acting anti-TL1A antibody, and SPY007, a novel long-acting anti-IL-17A/F antibody in preclinical development.The program is designed to treat patients with Hidradenitis Suppurativa, which is a skin condition that causes painful lumps deep within the skin, Spyre said.The clinical-stage company said it has initiated a mid-stage proof-of-concept trial evaluating dual inhibition of TL1A and IL-17A/F to treat Hidradenitis Suppurativa. The study is expected to enroll 150 adults. Topline results are expected late next year or early 2028.Price: 104.61, Change: -0.30, Percent Change: -0.29","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","LFSC","LENZ","SYRE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945935","title":"Spyre Therapeutics Announces Launch of Spy772 Program and Initiation of Phase 2 Skylight Trial in Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945935?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA5HMVSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993661","title":"Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993661","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993661?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT tria","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341779/0/en/spyre-therapeutics-announces-launch-of-spy772-program-and-initiation-of-phase-2-skylight-trial-in-hidradenitis-suppurativa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LFSC","LENZ","BK4007","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567890","title":"Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567890?lang=en_us&edition=fundamental","pubTime":"2026-08-08 22:40","pubTimestamp":1786200025,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Revolution Medicines (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","RVMD","BK4139","IE00BFTCPJ56.SGD","IE0002141913.USD","SYRE","CANC","LU0889565916.HKD","IE0009354923.USD","IDNA","LU0320765992.SGD","PTH","IE00B2B36J28.USD","LFSC","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626551","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626551","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626551?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:05","pubTimestamp":1786133100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341387/0/en/spyre-therapeutics-announces-grants-of-inducement-awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508141","title":"Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508141","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508141?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:32","pubTimestamp":1785979921,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CEO Turtle Cameron sells common shares worth $1.42 millionSpyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on Aug. 3 at weighted-average prices of $93.97 to $97.46.Ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLnGFtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657959733","title":"Spyre Therapeutics Inc : Jefferies Raises Target Price to $122 from $98","url":"https://stock-news.laohu8.com/highlight/detail?id=2657959733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657959733?lang=en_us&edition=fundamental","pubTime":"2026-08-05 12:45","pubTimestamp":1785905138,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN442029:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567255","title":"Spyre Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567255","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567255?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:21","pubTimestamp":1785878482,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummarySpyre Therapeutics IncSYRE.OQreported a quarterly adjusted loss of 36 cents per share for the quarter ended June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N44137O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561508","title":"Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657561508?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:14","pubTimestamp":1785874443,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026OverviewUS biotech firm's Q2 net loss and pretax loss were lower than analyst expectationsQ2 results included a $40 mln ga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","LFSC","SYRE","BK4585","BK4539","DSGN","PVLA","MEDI","BK4505","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657256955","title":"Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657256955","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657256955?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873720,"startTime":"0","endTime":"0","summary":"Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (\"SKYLINE\"), demonstrating best-in-class efficacy potential and a safety profile consistent wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","SYRE","BK4007","IBD","LFSC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654105391","title":"Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2654105391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654105391?lang=en_us&edition=fundamental","pubTime":"2026-07-25 09:25","pubTimestamp":1784942732,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Spyre Therapeutics, with a price target of $115.00. Suneja ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/spyre-therapeutics-syre-receives-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/spyre-therapeutics-syre-receives-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116922694","title":"Movement Alert｜Spyre Therapeutics Rises 11.41% in Regular Trading, Trading at $104.42","url":"https://stock-news.laohu8.com/highlight/detail?id=1116922694","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116922694?lang=en_us&edition=fundamental","pubTime":"2026-07-15 00:02","pubTimestamp":1784044976,"startTime":"0","endTime":"0","summary":"On July 15, Spyre Therapeutics rose 11.41% in regular trading, trading at $104.42 USD/share, with Turnover of $74.60 million.Within the Biotechnology sector where Spyre Therapeutics belongs,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":175,"code":"91000000","status":"200"}]}}